Document is current

Article History

Received: 30 October 2024

Accepted: 4 December 2025

First Online: 18 December 2025

Declarations

:

: The ECHAP-COVID program ( Evaluation et Comparaison d’une prise en charge multi-disciplinaire Hospitalière versus liste d’Attente en cas de symptoms Persistants après un episode aigu de COVID-19 ) is a prospective unicentric open-label randomized controlled trial that received ethical approval from CPP Est III by the Assistance Publique-Hôpitaux de Paris on 04/05/2022.The study was designed in accordance with the principles outlined in the Declaration of Helsinki and adhered to relevant French legislation governing research involving human participants. Written informed consent is obtained for every participant to the ECHAP-COVID program. Monitoring of consents during the study will be realized by a Clinical Research Assistant appointed by the sponsor. independent audit planned apart from the sponsor and investigators.Protocol amendments are submitted to regulatory authorities according to regulatory procedures and then sent to the centers by email. If the protocol is amended with substantial modification, the patient information form is updated.As this study is not considered as including high risk intervention nor with an invasive outcome, there is no data monitoring committee involved.

: Not applicable for this article. Written informed consent is obtained for every participant to the ECHAP-COVID program.

: CL reported non-financial support from Nordic Pharma, outside the submitted work. No other disclosures were reported.